Attendee search 

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Well renown venture capital firm in China.

Global Clinical Trials (GCT) is a premium contract-research organization (CRO) that offers support for the clinical Phase I-IV studies as well as post-marketing activities to Big Pharma, small and medium-sized biotech enterprises, groups and funds, as well as large universities and institutions. Headquartered in Princeton, USA, GCT offers both local and global support through 10 own operational offices in Bulgaria, Czech Republic, Georgia, Hungary, India, Kazakhstan, Latvia, Lithuania, Estonia, Moldova, Poland, Romania, Russia, Slovakia, Ukraine.
GCT team, that now consists of over 100 full-time clinical research professionals, gives individualized attention to each project and provides full range of services following the latest GCP, EMA and FDA guidelines at every stage of product development path. Our monitors and project managers are all certified clinicians experienced in GCP clinical research. Our experience, competent staff, close contact with the KOLs and the immense enrollment potential of the covered region ensure fast study start-up and compliance with the set timelines.
GCT owns 400 sq.m. (4300 ft2) Drug Storage and Distribution facility in St. Petersburg, Russia. It is fully equipped, disaster protected and has multiple modes of storage (ambient, climate controlled, refrigerated, frozen). High standards of work and client satisfaction are proved by the fact that more than 80% of the business come from repeat clients.
Since 2006 GCT is also an Exclusive Partner of “The White Nights” International ophthalmology congress in Russia.

My organization, OneThree Biotech, is a company that is dedicating our biology-driven AI expertise towards the fight against cancer. We’re combining systems biology with artificial intelligence to uncover new insights and build the next generation of drug discovery. We’ve built 14 different algorithms into our platform to provide insights across steps like target selection, compound mechanisms, toxicity and metabolism, and patient biomarkers at the beginning of the development process. This not only provides greater mechanistic insights, but also helps ensure a greater success rate for drugs entering preclinical development. Over the course of 2020 our founders have spoken at countless events like the BioData World Congress, Pharma and Patient USA, and various Reuters events culminating in our most recent accomplishment of winning Reuters' Entrepreneur Award for Health Solutions.

NanoTech Pharma focus on nanomedicine formulation development, located in New Jersey USA since year 2018. We have rich experiences in liposome and nanocrystal drug delivery systems. Our pipelines include 2 ANDA and several 505(b)(2) drugs, some of which have filed patents and are moving up to commercial scale.

Wuxi Biocity is a biopharmaceutical company mainly focusing on discovery, development, clinical trials and commercialization of "Best-in-Class" and "First-in-Class" original new drug of oncology and autoimmune diseases. Established in December 2017 in Wuxi, Biocity aims to benefit patients around the world as a pioneer pharmaceutical company in China with sustainable innovation ability and therapeutic products. With the noble mission of "Better Medicine for Better Life", our team always adhere to scientific evidence, while consider unfulfilled medical needs ahead of time, to achieve the goal of patient-centered, full-lifecycle disease management. Biocity's programs successfully entered into clinical stages within three years of efficient operation.



We are honored to have domestic and international academicians, well-known scientists, enterprise and policy specialists, clinical experts in particular, on our advisory board to guide Biocity's scientific, clinical, and strategic development. To reach our long-term goal of sustainable competitive advantages, we collaborate with the Wuxi government on multiple aspects to establish the "Biocity Innovation Institute for Translational Medicine". Thus we can further dig into the translational medical research from the discovery of disease mechanisms to the therapeutic applications of certain scientific achievements. Biocity Innovation Institute will strengthen our R&D ability and innovation capacity, therefore accelerate the popularization and enhancement of translational medicine in Wuxi, Jiangsu.



We have been recognized by many investment firms and intend to conduct an IPO in the very near future. With great efforts, we will bring safe and effective local innovative medicine at the best of times, to meet the increasing medical needs globally.

以尖端生命科学技术转化为核心，专注于ReproCore超微因子系列生物制品的研发、生产、销售、服务为主营业务，涉及医学康养、医学美容、健康调理、精准医疗等领域，以严谨的科学态度、严格的技术标准、完备的质量保障、一流的产品服务，致力于为广大消费者，特别是社会高端人群打造全生命周期的个性化健康定制咨询、产品、服务、管理于一体的健康生态平台。

Located at the High-Tech center, Silicon Valley, ZJ Future was established in 2013 as a bridge between China and the US to offer accelerating services for domestic enterprises with global perspectives. ​



With the vision of accelerating enterprise development and growth, we leverage the complementary advantages of North America, Europe, South America, and the Asia-Pacific regions to connect high-quality projects with industry leaders, promote academic communications and interactions in high-tech fields, aggregate global entrepreneurial and innovative resources, build an effective and efficient global innovation ecosystem, and develop high-level and multi-field cooperation in the fields of economy, trade, investment, science, and technology.

华润集团一级利润中心，聚焦生命科学领域投资与合作